Golden berry-derived 4β-hydroxywithanolide E for selectively killing oral cancer cells by generating ROS, DNA damage,

Chien-Chih Chiu1, Jo-Wen Haung, Fang-Rong Chang

  • 1Department of Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan.

Plos One
|May 25, 2013
PubMed
Abstract

Insights

4β-hydroxywithanolide (4βHWE) selectively kills oral cancer cells by inducing DNA damage and apoptosis, sparing normal cells. This natural compound shows promise for targeted cancer therapy and chemoprevention.

Area of Science:

  • Pharmacology
  • Cancer Biology
  • Natural Products Chemistry

Background:

  • Chemotherapy faces challenges due to cytotoxicity in normal cells.
  • Developing cancer-specific drugs with minimal side effects is crucial.
  • 4β-hydroxywithanolide (4βHWE) is investigated for its selective anti-cancer potential.

Purpose of the Study:

  • To evaluate 4β-hydroxywithanolide (4βHWE) for selective oral cancer cell killing.
  • To elucidate the underlying mechanisms of 4βHWE's action.
  • To assess its effects on normal fibroblast cells.

Main Methods:

  • Comparison of cell survival, oxidative stress, DNA damage, and apoptosis in oral cancer (Ca9-22) and normal fibroblast (HGF-1) cells treated with 4βHWE.
  • Assessment of reactive oxygen species (ROS) levels, mitochondrial depolarization, and DNA damage (comet assay, γ-H2AX/PI).
  • Cell cycle perturbation analysis (subG1, G1/G2/M arrest) and apoptosis induction assays (Annexin V/PI, p-ATR, caspase cleavage, PARP cleavage).

Main Results:

  • 4βHWE significantly reduced Ca9-22 cell numbers while minimally affecting HGF-1 cells.
  • Increased ROS, mitochondrial depolarization, and DNA damage were observed in cancer cells.
  • 4βHWE induced cell cycle arrest and apoptosis preferentially in oral cancer cells via ATR and caspase pathways.

Conclusions:

  • 4βHWE demonstrates selective cytotoxicity against oral cancer cells.
  • Mechanisms involve oxidative stress, DNA damage, cell cycle perturbation, and apoptosis induction.
  • Findings support 4βHWE's potential for oral cancer chemoprevention and therapy.